if it really does get rescheduled, I expect a lot of movement in this niche, thanks for bringing it up. wish we could add them to a portfolio here but definetly something to load up on in the near future
would love to, but the dataprovider doesn't have those like others have mentioned. Once we have more of a budget I can add them though
They reported a 27% increase in first-quarter earnings compared to last year, which is huge. And their revenue and total payment volume surpassed expectations, which is always a good sign. The new accounting method they're using includes stock-based compensation expenses and related taxes, and they've adjusted their financial results for the past few years to reflect this change. their adjusted earnings per share still beat analyst estimates by 15%, coming in at $1.08 per share instead of the expected $1.22
nice hub, thanks for creating it. looking into the future of medical industry now that AI is becoming more and more mainstream, medical industry usually takes a bit longer for new technologies to kick in, so looking into this now before it pops off due to it is a good idea. I've already added the tickers you suggested on that other thread but we should start looking into others in this field too
def interesting companies to look into. Should we have a specific AI and pharma related hub, these are a bit of a longer term plays imo, but we could add them into /h/pharma too
I agree, AI has yet to shake the pharma industry from the ground up. there are a lot of use cases that can be applied to AI like protein folding etc. Been looking for companies that are investing in this sort of thing, are there any you would recommend?
nice picks, I'm thinking also has some good future in this area, or
There's also they basically supply other companies with implementations, with so many companies that wants to go with AI they could be powering alot of these new companies popping up
kinda fitting for elon, knowing him he'll make a new line up named "candy" or something though.
I think so, they have solid fundamentals, they won't be going away soon. You're right that they're losing market share to big cloud providers that are making their own chips like gravitons though. Also apple has completely transitioned off of them too I believe. They do need to come up with some solution to this soon though.
It seems Walgreens is navigating a highly nuanced financial landscape this quarter. The hefty loss per share, primarily due to a $5.8 billion non-cash impairment charge related to VillageMD goodwill, paints a stark contrast against the positive note of an adjusted EPS increase of 3.4%. This duality mirrors the broader challenges in the retail and healthcare sectors, emphasizing the volatility and unpredictability inherent in these markets.
The narrowing of the fiscal 2024 adjusted EPS guidance reflects a cautious yet strategic approach in the face of a challenging retail environment in the U.S. It's clear that Walgreens is not just battling market forces but is also making concerted efforts to pivot and adapt through strategic portfolio reviews and cost-saving measures aimed at achieving a significant $1 billion in savings this year.
What stands out is the CEO's optimism and focus on customer engagement, value, and the pharmacy services execution, which appears to be a bright spot amidst the challenges. This strategic pivot towards enhancing value and engagement could be pivotal for Walgreens, especially as it aims to navigate through the retail challenges and capitalize on the pharmacy services sector's opportunities.
However, the substantial non-cash impairment charges and the negative free cash flow highlight the financial strains and the need for careful strategic adjustments. The company's efforts to focus on long-term value creation, alongside operational simplifications and strengths, underscore a deliberate strategy to navigate through these turbulent times.
In light of these mixed signals, investors might find Walgreens a challenging but potentially rewarding play if its strategic pivots and focus on pharmacy services and cost savings bear fruit. Yet, the critical factor will be its ability to adapt and evolve in a rapidly changing retail and healthcare landscape, making it a company to watch closely in the coming months.
They havent been able to capitalize on the massive investment they've gotten from the public it seems. It has been more 3 years since the whole thing happened, and I haven't seen anything that would change the original short position many hedge funds had for this company. They are still losing to Valve and other competitors. They haven't made any advancements. The company is just stale and I don't think it has anywhere to go at this point with their current leadership.
should've listened to you apperantly